Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.58 |
| ▸ | CA2 | P00918 | 11/20 | 0.58 |
| ▸ | CA12 | O43570 | 7/20 | 0.58 |
| ▸ | CA9 | Q16790 | 7/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28103316 | 0.99 | CA1 (0.59) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL14740749 | 0.96 | CA1 (0.57) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL16990184 | 0.91 | CA1 (0.54) | CA1CA2CA12CA9IDO1 | |
| SCHEMBL2822013 | 0.89 | CA1 (0.60) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL23835564 | 0.88 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040417 | 0.88 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040473 | 0.88 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040410 | 0.88 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL10191081 | 0.88 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL4640090 | 0.88 | CA1 (0.61) | CA1CA2CA12CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013033270-A2 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | CA1 2152/4885CA2 3650/4885CA12 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.